MAPK7

Across TCGA pan-cancer cohorts, MAPK7 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated MAPK7 data layer compared with 22 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher MAPK7 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated MAPK7 expression acts as an unfavorable survival marker, although some lineages such as LSCC show a favorable association.

PDAC, CCRCC, and LSCC are the cancer types where MAPK7 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	II,III,IV	0.304	0.523	.009	19	view →
CCRCC	OS	Median	III,IV	0.798	0.962	.028	11	view →
LSCC	OS	Tertile	All	0.971	0.837	.015	9	view →
LUAD	OS	Quartile	II,III,IV	0.293	0.839	.017	4	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

MAPK7–PDAC (DFS)

Open the PDAC breakdown →